Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.77 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.62 |
| ▸ | HINT1 | P49773 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19843948 | 1.00 | ADORA3 (0.77) | ADORA3HSP90B1HINT1NT5ECYP2C19 | |
| SCHEMBL4452551 | 1.00 | ADORA3 (0.77) | ADORA3HSP90B1HINT1NT5ECYP2C19 | |
| Phosphoric Acid SCHEMBL13857855 | 0.94 | ADORA3 (0.69) | ADORA3HSP90B1HINT1NT5ECYP2C19 | |
| SCHEMBL13769821 | 0.88 | ADORA3 (0.76) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL6671762 | 0.88 | ADORA3 (0.65) | ADORA3HSP90B1HINT1CYP2C19ADORA2B | |
| SCHEMBL23884966 | 0.87 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL10061853 | 0.87 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL13296249 | 0.87 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL2406009 | 0.87 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL19843949 | 0.87 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | disclosed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | disclosed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | ADORA3 30/4885HSP90B1 3514/4885HINT1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.